专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明公开

EP3648791A1 NOVEL NUCLEIC ACID MOLECULES 无效转让
公开(公告)号：EP3648791A1
公开(公告)日：2020-05-13
申请号：EP18740528.7
申请日：2018-07-03
申请人： CureVac AG
发明人： FOTIN-MLECZEK, Mariola , FIEDLER, Katja , KOWALCZYK, Aleksandra , HEIDENREICH, Regina
IPC分类号： A61K39/00 , A61K39/39 , A61K39/385 , C07K14/705 , C07K14/465 , C12N9/90

3. 发明公开

EP3781591A1 NOVEL RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATION 审中-公开
公开(公告)号：EP3781591A1
公开(公告)日：2021-02-24
申请号：EP19719234.7
申请日：2019-04-17
申请人： CureVac AG
发明人： LUTZ, Johannes , RAUCH, Susanne , HEIDENREICH, Regina , PETSCH, Benjamin
IPC分类号： C07K16/10 , C12N15/67

4. 发明公开

EP3595715A1 RNA VACCINE AND IMMUNE CHECKPOINT INHIBITORS FOR COMBINED ANTICANCER THERAPY 审中-公开
公开(公告)号：EP3595715A1
公开(公告)日：2020-01-22
申请号：EP18710886.5
申请日：2018-03-16
申请人： CureVac AG , Boehringer Ingelheim International GmbH
发明人： HEIDENREICH, Regina , FIEDLER, Katja , FOTIN-MLECZEK, Mariola , KOWALCZYK, Aleksandra , ELBERS, Knut , WURM, Melanie
IPC分类号： A61K39/395 , A61K39/00

5. 发明公开

EP3773702A2 NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION 审中-公开
公开(公告)号：EP3773702A2
公开(公告)日：2021-02-17
申请号：EP19715918.9
申请日：2019-04-05
申请人： CureVac AG
发明人： LUTZ, Johannes , RAUCH, Susanne , HEIDENREICH, Regina , PETSCH, Benjamin
IPC分类号： A61K39/12 , C12N15/67 , A61P31/14

6. 发明公开

EP3129050A2 POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT 审中-公开
标题翻译： POLYMERTRÄGER-CARGO-KOMPLEX ZUR VERWENDUNG ALS IMMUNSTIMULIERENDES MITTEL ODER ALS EIN ADJUVANS
公开(公告)号：EP3129050A2
公开(公告)日：2017-02-15
申请号：EP15717419.4
申请日：2015-04-01
申请人： CureVac AG
发明人： FOTIN-MLECZEK, Mariola , HEIDENREICH, Regina
IPC分类号： A61K39/39 , A61K47/62
CPC分类号： A61K39/385 , A61K39/12 , A61K39/145 , A61K39/155 , A61K39/205 , A61K47/6455 , A61K2039/53 , A61K2039/552 , A61K2039/55516 , A61K2039/55561 , A61K2039/572 , A61K2039/575 , A61K2039/6031 , A61K2039/6093 , A61K2039/622 , C12N7/00 , C12N15/117 , C12N2310/17 , C12N2320/31 , C12N2320/32 , C12N2760/16134 , C12N2760/16171 , C12N2760/18534 , C12N2760/18571 , C12N2760/20134 , C12N2760/20171
摘要： The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule. The present invention also provides pharmaceutical compositions, particularly vaccines, comprising the inventive polymeric carrier cargo complex and the second nucleic acid molecule, as well as the use of the inventive polymeric carrier cargo complex and the second nucleic acid molecule for transfecting a cell, a tissue or an organism, as a medicament, for therapeutic purposes as disclosed herein, and/or as an immunostimulating agent or adjuvant, e.g. for eliciting an immune response for the treatment or prophylaxis of diseases as mentioned herein. Finally, the invention relates to kits containing the inventive polymeric carrier cargo complex and the second nucleic acid molecule, the inventive pharmaceutical composition and/or the inventive vaccine or any of its components in one or more parts of the kit.
摘要翻译：本发明涉及一种聚合物载体载体复合物，其包含至少一种核酸分子和作为优选无毒且非免疫原性的聚合载体二硫键 - 交联的阳离子组分作为载体用作免疫刺激剂或作为佐剂，其中聚合载体货物复合物与编码蛋白质或肽的至少一个第二核酸分子组合施用。与第二核酸分子组合施用的本发明的聚合物载体货物复合物允许在体内和体外有效地将核酸转染到细胞中和/或用于诱导优先依赖于核酸的先天和/或适应性免疫应答作为货物运输的酸和第二核酸分子。本发明还提供药物组合物，特别是疫苗，其包含本发明的聚合物载体货物复合物和第二核酸分子，以及本发明的聚合物载体货物复合物和第二核酸分子用于转染细胞，组织或作为药物的生物体，用于本文公开的治疗目的，和/或作为免疫刺激剂或佐剂，例如，用于引发用于治疗或预防本文所述的疾病的免疫应答。最后，本发明涉及在试剂盒的一个或多个部分中含有本发明的聚合物载体货物复合物和第二核酸分子，本发明的药物组合物和/或本发明疫苗或其任何组分的试剂盒。

7. 发明公开

EP3893909A2 KRAS VARIANT MRNA MOLECULES 审中-公开
公开(公告)号：EP3893909A2
公开(公告)日：2021-10-20
申请号：EP19828159.4
申请日：2019-12-06
申请人： CureVac AG
发明人： AGGARWAL, Amit , FIEDLER, Katja , GNAD-VOGT, Ulrike , HEIDENREICH, Regina , KONERU, Mythili , PLOWMAN, Gregory D.
IPC分类号： A61K38/00

8. 发明公开

EP3500295A2 RNA FOR CANCER THERAPY 审中-公开
公开(公告)号：EP3500295A2
公开(公告)日：2019-06-26
申请号：EP17761442.7
申请日：2017-08-14
申请人： CureVac AG
发明人： FOTIN-MLECZEK, Mariola , KOWALCZYK, Aleksandra , HEIDENREICH, Regina , GNAD-VOGT, Ulrike , KLINKHARDT, Ute , FIEDLER, Katja
IPC分类号： A61K39/39

9. 发明公开

EP3374504A2 OPTIMIZED NUCLEIC ACID MOLECULES 审中-公开
公开(公告)号：EP3374504A2
公开(公告)日：2018-09-19
申请号：EP16794593.0
申请日：2016-11-09
申请人： CureVac AG
发明人： BAUMHOF, Patrick , RAUCH, Susanne , KOWALCZYK, Aleksandra , LUTZ, Johannes , JASNY, Edith , PETSCH, Benjamin , THESS, Andreas , SCHLAKE, Thomas , FOTIN-MLECZEK, Mariola , HEIDENREICH, Regina , LAZZARO, Sandra , DÖNER, Fatma , GROßE, Wolfgang
IPC分类号： C12N15/00 , A61K48/00 , A61K39/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/145 , A61K2039/53 , A61K2039/575 , C07K14/205 , C07K2319/00 , C07K2319/40 , C12N15/00 , C12N2760/16122 , C12N2760/16134
摘要： The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g. selected among nucleic acid moieties encoding a polypeptide element, such as a secretory signal peptide (SSP), a multimerization element (dimerization, trimerization, tetramerization and oligomerization), a virus like particle (VLP) forming element, a transmembrane element, a dendritic cell targeting element, an immunological adjuvant element, an element promoting antigen presentation; a 2A peptide; a peptide linker element, elements that extend protein half-life, and/or any other polypeptide or protein. Non-coding nucleic acid moieties may be selected e.g. from the group comprising 3′-UTR, 5′-UTR, IRES element, miRNA moiety, histone stem loop, poly(C) sequence, polyadenylation signal, polyA-sequence. The optimized nucleic acid molecule can further be characterized by the presence of at least one modified nucleoside. The versatility of the present invention allows for rational design of a large variety of different nucleic acid molecules with desired properties.

10. 发明公开

EP3310384A1 VACCINE COMPOSITION 审中-公开
标题翻译：疫苗组合物
公开(公告)号：EP3310384A1
公开(公告)日：2018-04-25
申请号：EP16736397.7
申请日：2016-06-17
申请人： CureVac AG
发明人： HIPP, Madeleine , HEIDENREICH, Regina , FOTIN-MLECZEK, Mariola , BAUMHOF, Patrick , LUTZ, Johannes , KOWALCZYK, Aleksandra
IPC分类号： A61K39/39 , A61K39/00
CPC分类号： A61K39/145 , A61K39/00 , A61K39/12 , A61K39/205 , A61K39/39 , A61K2039/53 , A61K2039/55505 , A61K2039/55561 , A61K2039/55566 , A61K2039/575 , C12N2760/16134 , C12N2760/20134 , Y02A50/386 , Y02A50/388 , Y02A50/412
摘要： A composition or combination comprising at least a first immunogenic component and at least a second adjuvant component, wherein the first immunogenic component comprises at least one nucleic acid molecule encoding at least one epitope of at least one antigen, and wherein the second adjuvant component comprises at least one immune potentiator compound and/or at least one delivery system compound.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式